Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ateganosine + tislelizumab
- Development stage
- Unknown
- Lead developer
- Maia Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ateganosine + tislelizumab is a combination therapy being developed by MAIA Biotechnology for the treatment of colorectal cancer (CRC). It consists of ateganosine (THIO), a first-in-class small molecule telomere-targeting agent, and tislelizumab, a humanized monoclonal antibody targeting the PD-1 immune checkpoint. Ateganosine acts as a telomerase substrate that is preferentially incorporated into the telomeres of cancer cells, leading to telomere capping disruption, genomic instability, and immunogenic cell death. This process is intended to prime the tumor microenvironment, enhancing the efficacy of the subsequent PD-1 inhibition by tislelizumab, which restores T-cell activity against the cancer. The combination is currently being evaluated in Phase 2 clinical trials.
- Other names
- THIO + tislelizumab6-thio-2'-deoxyguanosine + tislelizumab
02
Targets
telomeric G4 (Telomeric DNA G-quadruplex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ateganosine + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ateganosine + tislelizumab.